Novel Imaging Agent More Effectively Monitors Impact of Treatment in Lung, Prostate Cancers

December 4, 2015

A method to better trace changes in cancers and treatment of the prostate and lung without the limitations associated with radiation has been developed (Scientific Reports. doi:10.1038/srep16214).

The researchers developed a new imaging agent they named ProCA1.GRPR, and demonstrated that it leads to strong tumor penetration and is capable of targeting the gastrin-releasing peptide receptor expressed on the surface of diseased cells, including prostate, cervical, and lung cancer cells.

Read the full article.